New Long-Lasting Alternative to Botox is On the Way

A new product currently known as “RT002” is being developed by Revance Therapeutics as a long-lasting alternative to Botox.

Also known as Daxibotulinumtoxin A, this product is injected into the target muscles just like Botox, but is shown to last up to 6 months instead of the 3 to 4 months that Botox lasts.  This means patients will have to come in less often for their treatments, and it will be easier for them to maintain their results.

This also means that you can time your treatments along with your filler touch-ups and get everything done in one visit twice per year.

RT002 is currently in Phase 3 clinical trials.  Once the studies are complete, the product will enter Phase 4 where it has the potential to be approved by the FDA for public use.

In a study with more than 2,500 patients, Revance Therapeutics expects to show that their product is just as safe as Botox, but can last twice as long.  They plan to enter into Phase 4 by early 2019, which would mean the public release date will be some time in 2020.

RT002 is currently being studied for cosmetic use but could be used to treat any of the same conditions that Botox is currently used to treat. Botox Cosmetic is FDA approved to treat the glabella (lines between the brows), crow’s feet, and forehead lines.  Botox is also FDA approved to treat many medical conditions, including hyperhidrosis (excess sweating).  Treatment of hyperhidrosis currently lasts about 6 to 12 months with Botox.  Hopefully, RT002 will double that as well, leading to a 12 to 24-month benefit for the treatment of excess sweating.

Many times products like this are purchased by more established cosmetic companies, like Allergan, the maker of Botox. That is what happened with Kybella!

We will have to wait and see if Allergan or one of its competitors will purchase RT002 or if it will stay with its own company, Revance Therapeutics.  Either way, we will keep a close eye on this product, also known as Daxibotulinumtoxin A, as it becomes available to the public.